Krishen Sud’s Sivik Global Loves These Healthcare Stocks

McKesson Corporation (NYSE:MCK) was Sivik’s only holding that remained in its top five from the end of 2014, getting a slight bump to fourth from fifth, with the holding being marginally increased by 300 shares during the quarter to an even 35,000 (Sivik likes round numbers). Shares of McKesson Corporation (NYSE:MCK) were up by just over 9% during the first quarter, which contributed to the rise in value of Sivik’s position, to $7.92 million. McKesson Corporation (NYSE:MCK) announces its fiscal fourth quarter results on May 12. The supplier of pharmaceutical products raised its FY 2015 guidance in early February causing shares to spike over the next two days, which was good news for prominent investors Daniel Och, Robbins, and Leon Copperman.

Along with Gilead, Biogen Inc (NASDAQ:BIIB) was one of the hottest biotech stocks among billionaires heading into 2015, with Stanley Druckenmiller at the head of that billionaires pack, which included six other billionaire investors. Sivik was also bullish on Biogen Inc (NASDAQ:BIIB) heading into 2015, though he lowered his exposure to the stock during the first quarter, slashing his position by 22% to 17,500 shares valued at $7.39 million. Biogen Inc (NASDAQ:BIIB) missed earnings estimates today which has sent shares tumbling, though it remains up by more than 18% for the year. While Piper Jaffray has cut its price target on Biogen to $485 from $500 following the earnings report, that still leaves a better than 20% upside on the stock, which is trading at just over $400.

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) was a little further down the list for Sivik, with the fund holding a position of 80,000 shares valued at $4.98 million, the position increased by 34% during the first quarter. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) is another stock that billionaires, including George Soros, are crazy about, and with good reason; shares have gained 12% this year and more than 50% since the beginning of 2014. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announces its own quarterly earnings next Thursday, with Wall Street expecting earnings per share of $1.25, a 3% rise over the first quarter of 2014. Teva had beaten estimates for five straight quarters before narrowly missing the mark with its most recent earnings report for the fourth quarter of 2014, by just 0.04%.

Disclosure: None